Besides a trend towards a higher expression of OX40 and OX40L in patients with FAB M3 and M5 AML cases, neither molecule was differentially expressed in any of the FAB subtypes, and a significant difference of OX40L expression could be observed only in M3 patients compared to M1. This evidence concerns the gene TNFSF4 and acute myeloid leukemia.